Laboratory of Clinical Chemistry and Radio-immunology, UZ Brussel, Brussel, Belgium.
Clin Chim Acta. 2010 Sep 6;411(17-18):1348-53. doi: 10.1016/j.cca.2010.05.032. Epub 2010 May 25.
Serum free thyroxine (FT4) testing in pregnancy is known to be challenging for immunoassays (IAs). We verified the reliability of FT4 results by 3 commercial IAs throughout pregnancy, by comparison of the pattern to that obtained with an equilibrium dialysis isotope dilution-mass spectrometry (ED ID-MS) candidate reference measurement procedure.
Pregnant females (107) and age-matched non-pregnant controls (26) were enrolled. The IAs tested were those performed on the Cobas 6000 (Roche Diagnostics), ARCHITECT i2000SR (Abbott Diagnostics) and Immulite 2000 (Siemens Healthcare) platforms.
Compared to the controls (mean FT4: 18.2pmol/L), ED ID-MS gave in the late first trimester pregnancy an 8.8% lower (p<0.05) mean; in the second trimester it was 29.1% lower (p<0.001), to stabilize in the third trimester (p=0.99). Similar observations were made for the Cobas and Immulite IAs. The ARCHITECT IA showed no significant decrease in the late first trimester (mean 13.5pmol/L versus 13.6pmol/L in controls), but a significant, less pronounced, decrease in the second and third trimesters (15% and 14.4%, respectively). All IAs were susceptible towards alterations in T4 binding proteins during pregnancy.
We proved that IAs may give a FT4 pattern during pregnancy similar to that obtained by ED ID-MS.
免疫分析(IA)检测妊娠时血清游离甲状腺素(FT4)具有挑战性。我们通过比较与平衡透析同位素稀释-质谱(ED ID-MS)候选参考测量程序获得的模式,验证了 3 种商业 IA 在整个妊娠期间 FT4 结果的可靠性。
招募了 107 名孕妇和 26 名年龄匹配的非孕妇对照者。检测的 IA 是在 Cobas 6000(罗氏诊断)、ARCHITECT i2000SR(雅培诊断)和 Immulite 2000(西门子医疗保健)平台上进行的。
与对照组(平均 FT4:18.2pmol/L)相比,ED ID-MS 在妊娠晚期第 1 个三分之一期给出了 8.8%(p<0.05)的平均降低;在第 2 个三分之一期,降低了 29.1%(p<0.001),在第 3 个三分之一期稳定(p=0.99)。类似的观察结果也见于 Cobas 和 Immulite IA。ARCHITECT IA 在妊娠晚期第 1 个三分之一期没有显著降低(平均 13.5pmol/L,对照组为 13.6pmol/L),但在第 2 和第 3 个三分之一期有显著降低,分别为 15%和 14.4%。所有的 IA 都容易受到妊娠期间 T4 结合蛋白改变的影响。
我们证明了 IA 在妊娠期间可能会产生与 ED ID-MS 相似的 FT4 模式。